Bruker AXS Establishes New X-Ray Life-Sciences Laboratory For Protein Crystallization and Macromolecular Structure Determination.DELFT Delft (dĕlft), city (1994 pop. 91,941), South Holland prov., W Netherlands. It has varied industries and is noted for its ceramics (china, tiles, and pottery) known as delftware. Founded in the 11th cent. , Netherlands -- Bruker AXS, Inc., a leading global provider of advanced X-ray solutions for life sciences and advanced materials research, announces today the establishment of a new laboratory in Delft, equipped with the latest state-of-the-art X-ray instrumentation and technologies for the determination of 3D crystal structures of small molecules and proteins. This laboratory will incorporate robotic facilities for the high-throughput preparation of protein crystallization Crystallization The formation of a solid from a solution, melt, vapor, or a different solid phase. Crystallization from solution is an important industrial operation because of the large number of materials marketed as crystalline particles. screens, combined with the Crystal Farm(TM) incubation and imaging system for crystal growth. Dr. Eric Hovestreydt, Managing Director of Bruker AXS B.V. in Delft, explained: "The X-ray Life-Sciences Laboratory will continuously improve our X-ray instrumentation, software and methods through close collaborations with and feedback from the crystallographers using it. The X-ray Life-Sciences Laboratory is part of our continuing commitment to develop state-of-the-art tools for structural proteomics. By further strengthening our ties with the structural biology community in Europe and beyond, this lab will drive the development of new applications and technologies. We hope to push the boundaries of existing technologies in structural proteomics and crystallography through extensive collaborations with leading investigators." Professor Jan Pieter Abrahams, Project Leader of the Cyttron research project, 'A Window on the Molecular Machinery of Life', at the University of Leiden, commented: "The Cyttron consortium, of which Bruker AXS is a key partner, aims to extend and integrate existing technology platforms in structural biology, with the ultimate aim of visualizing and modeling living cells with atomic resolution. The research facilities which Bruker AXS has made available to the partners of the Cyttron consortium are absolutely essential for reaching this objective." ABOUT BRUKER BIOSCIENCES (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ) Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. , headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on x-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. . Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC NBC in full National Broadcasting Co. Major U.S. commercial broadcasting company. It was formed in 1926 by RCA Corp., General Electric Co. (GE), and Westinghouse and was the first U.S. company to operate a broadcast network. ) detection products for defense and homeland security. For more information: www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion